Denali Therapeutics Total Assets Growth & History (DNLI)
Denali Therapeutics's total assets was $1.14B for fiscal 2025.
View full Denali Therapeutics company overviewDenali Therapeutics annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.14B | −$229.3M | −16.69% |
| 2024 | 2024-12-31 | $1.37B | $220.3M | +19.09% |
| 2023 | 2023-12-31 | $1.15B | −$306.3M | −20.98% |
| 2022 | 2022-12-31 | $1.46B | $56.1M | +3.99% |
| 2021 | 2021-12-31 | $1.40B | −$200.1M | −12.47% |
| 2020 | 2020-12-31 | $1.60B | $1.05B | +189.98% |
| 2019 | 2019-12-31 | $553.2M | −$108.8M | −16.43% |
| 2018 | 2018-12-31 | $662.0M | $175.3M | +36.01% |
| 2017 | 2017-12-31 | $486.7M | — | — |
Denali Therapeutics quarterly total assets
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.16B | −$8.3M | −0.71% |
| Q1 2026 | 2026-03-31 | $1.27B | −$5.3M | −0.42% |
| Q4 2025 | 2025-12-31 | $1.14B | −$229.3M | −16.69% |
| Q3 2025 | 2025-09-30 | $1.06B | −$398.4M | −27.40% |
| Q2 2025 | 2025-06-30 | $1.17B | −$336.3M | −22.38% |
| Q1 2025 | 2025-03-31 | $1.27B | −$309.7M | −19.59% |
| Q4 2024 | 2024-12-31 | $1.37B | $220.3M | +19.09% |
| Q3 2024 | 2024-09-30 | $1.45B | $217.2M | +17.56% |
| Q2 2024 | 2024-06-30 | $1.50B | $196.8M | +15.07% |
| Q1 2024 | 2024-03-31 | $1.58B | $171.7M | +12.19% |
| Q4 2023 | 2023-12-31 | $1.15B | −$306.3M | −20.98% |
| Q3 2023 | 2023-09-30 | $1.24B | $9.2M | +0.75% |
| Q2 2023 | 2023-06-30 | $1.31B | $13.3M | +1.03% |
| Q1 2023 | 2023-03-31 | $1.41B | $88.5M | +6.70% |
| Q4 2022 | 2022-12-31 | $1.46B | $56.1M | +3.99% |
| Q3 2022 | 2022-09-30 | $1.23B | −$222.4M | −15.34% |
| Q2 2022 | 2022-06-30 | $1.29B | −$217.4M | −14.40% |
| Q1 2022 | 2022-03-31 | $1.32B | −$227.0M | −14.67% |
| Q4 2021 | 2021-12-31 | $1.40B | −$200.1M | −12.47% |
| Q3 2021 | 2021-09-30 | $1.45B | $379.7M | +35.47% |
| Q2 2021 | 2021-06-30 | $1.51B | $862.5M | +133.23% |
| Q1 2021 | 2021-03-31 | $1.55B | $852.0M | +122.44% |
| Q4 2020 | 2020-12-31 | $1.60B | $1.05B | +189.98% |
| Q3 2020 | 2020-09-30 | $1.07B | $467.3M | +77.50% |
| Q2 2020 | 2020-06-30 | $647.3M | $9.7M | +1.53% |
| Q1 2020 | 2020-03-31 | $695.9M | $19.3M | +2.85% |
| Q4 2019 | 2019-12-31 | $553.2M | −$108.8M | −16.43% |
| Q3 2019 | 2019-09-30 | $603.0M | $58.5M | +10.74% |
| Q2 2019 | 2019-06-30 | $637.6M | $65.5M | +11.46% |
| Q1 2019 | 2019-03-31 | $676.6M | $62.6M | +10.20% |
| Q4 2018 | 2018-12-31 | $662.0M | $175.3M | +36.01% |
| Q3 2018 | 2018-09-30 | $544.5M | — | — |
| Q2 2018 | 2018-06-30 | $572.1M | — | — |
| Q1 2018 | 2018-03-31 | $614.0M | — | — |
| Q4 2017 | 2017-12-31 | $486.7M | — | — |
Denali Therapeutics total assets trends
Over the last five fiscal years, Denali Therapeutics's total assets decreased from $1.60B to $1.14B, a change of −$459.4M. The latest reported quarter, Q2 2026, shows $1.16B.
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Denali Therapeutics source filings ↗